Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that debentureholders have converted $1.4 million of principal into common shares at $0.32 per share, issuing 4,375,000 shares. This conversion represents 35% of the company's outstanding debenture principal of $4 million, significantly strengthening the balance sheet as Ocumetics prepares for key milestones in its ongoing patient study program.
The conversion of debt into equity is expected to improve the company's financial flexibility and reduce ongoing interest costs while aligning investor interests with the continued advancement of Ocumetics' technology platform and clinical development objectives. The company is actively managing its investments and stakeholder relationships as it advances toward key regulatory milestones, including preparation for its planned Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration.
"These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision," said Dean Burns, President and CEO of Ocumetics. "We are actively managing our investments and stakeholder relationships as we continue to advance our patient study and focus on achieving the next major milestones for the Company."
Ocumetics is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company is in the first-in-human early feasibility study phase of a dynamic intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses and without perceptible time lag.
The debt reduction strengthens Ocumetics' financial position as it continues to advance its patient study program. The company's technology, if successful, could transform the field of ophthalmology by offering a state-of-the-art intraocular lens that mimics natural vision. This milestone is crucial for Ocumetics as it seeks to move closer to commercialization and regulatory approval.
For further information, visit the original release: NewMediaWire.
